Investigational drug · Phase 3
Etoricoxib
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gout Arthritis, Gout Attack, Acute Low-back Pain.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
1 still active
All registered trials
122
Any phase or sponsor naming "Etoricoxib"
First trial start
2024
May 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Etoricoxib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gout Arthritis
- Gout Attack
- Acute Low-back Pain
- Muscle Spasm; Back Pain
- Pain Management
- Osteoarthritis
- Bursitis
- Tendinitis
- Synovitis
Approved drugs for the same conditions: Gout · Osteoarthritis · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "Etoricoxib" as an intervention, largest first.
Organon and CoIndustry
NCT01685424 · 79,189 participants · Start Jun 30, 2006 · Primary completion Mar 1, 2015
Drug: Etoricoxib · For: Osteoarthritis; Rheumatoid Arthritis; Ankylosing Spondylitis and 2 more
Organon and CoIndustry
NCT01077843 · 27,381 participants · Start Aug 17, 2009 · Primary completion Jul 1, 2015
Drug: Etoricoxib; Other Cox-2 inhibitors and 1 more · For: Ankylosing Spondylitis
- A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00250445 · 23,498 participants · Start Jan 2003 · Primary completion May 2006
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Rheumatoid Arthritis,Osteoarthritis
Organon and CoIndustry
NCT01327638 · 21,108 participants · Start Feb 15, 2011 · Primary completion Sep 24, 2018
Drug: etoricoxib; Other COX-2 inhibitor and 1 more · For: Spondylarthropathies; Spondylitis, Ankylosing
- Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092703 · 6,000 participants · Start Jun 27, 2002 · Primary completion Nov 1, 2003
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Osteoarthritis
- Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092742 · 4,086 participants · Start Feb 2003 · Primary completion Dec 2005
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Rheumatoid Arthritis
- A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01208181 · 1,404 participants · Start Sep 27, 2010 · Primary completion Jun 9, 2014
Drug: Etoricoxib 60 mg; Etoricoxib 90 mg and 2 more · For: Arthritis, Rheumatoid
Organon and CoIndustry
NCT01294696 · 1,261 participants · Start Oct 2010 · Primary completion Jan 2013
Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) · For: Osteoarthritis
- Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00242489 · 1,167 participants · Start Jun 1998 · Primary completion Feb 1999
Drug: MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks); Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks · For: Osteoarthritis
- A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01208207 · 1,015 participants · Start Sep 27, 2010 · Primary completion Nov 12, 2014
Drug: Part I - etoricoxib 60 mg; Part I - etoricoxib 90 mg and 10 more · For: Spondylitis, Ankylosing
Newest research
PubMed records naming it or its code names, newest first.
- Effects of nanoemulsion of banana (Musa acuminata) leaf extract on ALP, osteocalcin, VEGF, and CD31 expression in orthodontic mechanical force application in Wistar rats (in vivo).
Triwardhani A, Putranti NAR, Rahmah RY, et al. · J Taibah Univ Med Sci 2026
- Primary hypertrophic osteoarthropathy type 2 presenting as an acromegaly mimic with enteropathy.
Kumar S, Khatri SJ, Sreevatsa T, et al. · JCEM Case Rep 2026
- Non-Monotonic Glass Transition Behavior as a Molecular Signature of Strong Interactions in Co-Amorphous and Crystalline Celecoxib-Etoricoxib Systems.
Knapik-Kowalczuk J, Mathew M, Poloczek P, et al. · Mol Pharm 2026
- Study of Transdermal Buprenorphine Patch versus Oral Etoricoxib for Postoperative Pain Management after Total Knee Arthroplasty: A Randomized Comparative Open-label Study.
Sneha S, Bagga A, Singh D, et al. · Ann Afr Med 2026
- Effectiveness of etoricoxib on bone microarchitecture in PHO patients: A 12-month longitudinal study assessed by HR-pQCT.
Zhou R, Li Y, Qi X, et al. · Bone 2026
- [Efficacy of celecoxib, diclofenac, etoricoxib, ibuprofen, ketoprofen and naproxen in low back pain with or without nerve root pain: Systematic review of literature and meta-analysis of randomized controlled trials].
Alfieri P, Landry M, Boussageon R · Therapie 2026
Also in development for Gout Arthritis
- Etoricoxib fixed doseEtoriPhase 32 trials
Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain
- SSGJ-613Phase 21 trial
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Gout Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.